Evidence map›Paper›PMID 17714739›Full record

ArticleMutation research2008

The spectra of large second-step mutations are similar for two different mouse autosomes.

Elizabeth Kasameyer, Lanelle Connolly, Michael Lasarev, Mitchell S Turker

Open access · greenAbstract read
In one paragraph

Article in Mutation research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Elizabeth KasameyerCenter for Research on Occupational and Environmental Toxicology (CROET), Oregon Health & Sciences University, Portland, OR 97239, USA.
Lanelle Connolly
Michael Lasarev
Mitchell S Turker
Oregon Health & Science University · US

Funding

CANCER, AGING, AND MUTATIONR01CA076528 · NCI · OREGON HEALTH AND SCIENCE UNIVERSITY · PI TURKER, MITCHELL S · 1999 to 2003
$1.0M
Autosomal Mutagenesis and Polycystic Kidney DiseaseR21DK074742 · NIDDK · OREGON HEALTH & SCIENCE UNIVERSITY · PI TURKER, MITCHELL S · 2006 to 2007
$306k
NCI NIH HHS CA 76528NCI NIH HHS R01 CA076528NIDDK NIH HHS DK 074742NIDDK NIH HHS R21 DK074742
6 · The paper itself

Abstract

Loss of tumor suppressor gene expression via mutations plays a critical role in cancer development, particularly when occurring in heterozygous cells. These so-called "second-step" mutational events are often large in size and arise most often from chromosome loss, mitotic recombination, or interstitial deletion. An open question in cancer research is whether different chromosomes are equally susceptible to formation of large mutations, or alternatively if the unique sequence of each chromosome will lead to chromosome-specific mutational spectra. To address this question, the spectra of second-step mutations were determined for chromosomes 8 and 11 in Aprt and Tk mutants, respectively, isolated from primary kidney clones heterozygous for both loci. The results showed that the spectra of large mutational events were essentially the same. This observation suggests that internal and external cellular environments provide the driving force for large autosomal mutational events, and that chromosome structure per se is the substrate upon which these forces act.

Indexed as

Chromosome AberrationsChromosomesMutationAdenine PhosphoribosyltransferaseAnimalsBase SequenceChromosome DeletionHeterozygoteMiceMice, Inbred C57BLRecombination, GeneticSequence DeletionThymidine KinaseAdenine PhosphoribosyltransferaseThymidine Kinase

Identifiers

PMID17714739
PMCPMC2233933
OpenAlexW2101665184

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.